High viral load carriage of EBV is one of the risks for PTLD in transplant recipients. We reviewed retrospectively in pediatric renal transplant recipients with EBV seronegative. EBV loads in peripheral blood and EBV-CTLs were measured every 1-3 months in 13 @entity1 after grafting. Immunosuppressants were reduced when the @entity1 were considered to have persistent high EBV loads (>1000 copies/ gDNA for over six months). All showed primary @entity2025 : six with asymptomatic persistent high EBV loads (group A) and seven with neither EBV-associated symptoms nor persistent high EBV loads (group B). No @entity1 developed PTLD in either group. Chronic rejection occurred in one @entity1 in group A after immunosuppressants' reduction. There was no difference in @entity8 rates between the two groups. The maximum and increase rates in EBV loads were significantly higher in group A. The CTLs' percentage was significantly lower in group A when EBV loads first rose above 100 copies/ g DNA. This study suggests the possibility that EBV loads and CTLs' monitoring may be useful for avoidance of PTLD, as @entity1 with asymptomatic persistent high EBV loads had higher EBV loads and lower percentages of CTLs.

Asymptomatic high XXXX in pediatric renal transplant recipients.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction'] @entity2025 :: ('MESH:D020031', 'Disease') :: ['EBV infection']
@entity2025 :: (MESH:D020031,Disease) :: ['Epstein-Barr viral load carriage']
